Historically lower, prevalence is increasing rapidly, currently estimated at 30 – 34%. This region is notable for the "Lean MASLD" phenotype, occurring in individuals with a normal Body Mass Index (BMI) [⁹,⁷].

Estimates range from 25% to 30%. While the overall prevalence is lower than in North America, the aging demographic contributes to a higher burden of advanced hepatic fibrosis [⁶,⁸].

The Middle East and North Africa (MENA) region reports the highest global prevalence, ranging from 36% to 42%. In Egypt, prevalence exceeds 40%, correlating with high regional rates of insulin resistance [⁶].

In individuals with a BMI > 35 kg/m\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$^{2}$\end{document}2, prevalence exceeds 90% [⁷].

Recent evidence suggests that MASLD affects approximately 22% of adults with Type 1 Diabetes, highlighting the impact of exogenous insulin-related weight gain and metabolic health in this cohort [⁴].

T2DM independently doubles the risk of hepatocellular carcinoma and liver-related mortality, significantly accelerating the transition from simple steatosis to advanced fibrosis [³⁰,³¹,³²].

Excess adiposity and atherogenic dyslipidemia increase the hepatic fatty acid load, triggering chronic oxidative stress [⁵,³³,⁶].

Variants such as PNPLA3 (impaired lipid droplet hydrolysis) and TM6SF2 (disrupted VLDL export) significantly influence disease susceptibility and the velocity of fibrosis progression [¹³,²⁷,³⁴].

High-calorie diets rich in fructose and saturated fats are potent stimulators of fat synthesis. Fructose is particularly damaging as it bypasses normal metabolic checks to drive triglyceride production [¹³,¹⁶,¹⁴].

Small-intestinal bacterial overgrowth promotes increased intestinal permeability. This facilitates the translocation of lipopolysaccharides (LPS) into the portal circulation, activating Toll-like receptors and exacerbating hepatocellular injury [²⁵,¹⁵].

Chronic intermittent hypoxia associated with OSA induces systemic oxidative stress and sympathetic overactivity, which intensify hepatic inflammatory signaling [²⁵,¹³,¹⁹].

Hypothyroidism: Low thyroid hormones decrease the liver’s ability to oxidize fat and export VLDL [³³,⁶].

Hyperuricemia: High uric acid promotes insulin resistance and stresses liver mitochondria [²²,²⁴].

Polycystic Ovary Syndrome (PCOS): Hyperinsulinemia in PCOS promotes direct hepatic fat production [¹³,¹⁹].

This phenotype is strongly associated with the PNPLA3 variant, explaining the presence of significant hepatic fat despite lower systemic adiposity [⁴,¹³].

MASLD is a primary driver of primary liver malignancy. Distinctively, HCC in the context of MASLD frequently occurs in the absence of established cirrhosis, suggesting that lipotoxicity-induced DNA damage and chronic oxidative stress can initiate malignant transformation independently of advanced fibrosis [³⁵,³⁶,³⁷,³⁸].

MASLD is associated with a 60% increase in CRC risk [³⁹]. Pathophysiology likely involves the disruption of the gut-liver axis and the systemic elevation of insulin-like growth factor 1 (IGF-1), which promotes colonic epithelial proliferation and inhibits apoptosis [⁴⁰].

MASLD is linked to a 20 – 40% higher incidence of breast cancer, particularly in postmenopausal women. The proposed mechanism involves the aromatization of androgens in adipose tissue and the resulting estrogenic stimulation of breast and uterine tissues [⁴¹,³⁹].

Recent data indicate an association between MASLD and more aggressive phenotypes of thyroid cancer. Furthermore, systemic inflammatory cytokines – specifically IL-6 and TNF-\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\alpha$\end{document}α – may synergize with environmental factors to increase lung cancer risk, though obesity remains a significant confounding variable in these cohorts [⁴¹].

MASLD independently raises the risk of incident heart failure, particularly Heart Failure with preserved Ejection Fraction (HFpEF), by approximately 50% [⁴²,⁴³].

Patients frequently exhibit subclinical changes, including left ventricular hypertrophy and impaired diastolic filling, even in the early stages of liver fat accumulation [⁴²].

There is a robust association with Atrial Fibrillation, likely driven by pro-inflammatory cytokines originating from both the liver and epicardial adipose tissue [⁴²,⁴³,⁴⁴].

MASLD is associated with a 60% higher risk of CRC and a significant increase in colorectal adenomas. This association is strongest in patients with advanced fibrosis, necessitating vigilant screening [⁴⁰,⁴⁶,³⁹].

Increased risks are noted for esophageal and gastric cancers [⁴¹]. Emerging evidence also suggests a higher incidence of breast and thyroid malignancies, often presenting with more aggressive clinical features [³⁵,⁴¹].

MASLD is an independent risk factor for CKD. Pro-inflammatory and pro-fibrotic signals (such as TGF-\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\beta$\end{document}β) released by the liver promote glomerular damage and decline renal function [⁴³,³⁴].

While insulin resistance drives MASLD, the presence of hepatic steatosis conversely makes glycemic control more difficult in patients with T2DM, increasing the likelihood of diabetic microvascular complications [⁴⁷,²⁹].

While lab ranges vary, an ALT > 30 U/L is increasingly recognized as the threshold for further evaluation in adults [⁴].

To confirm MASLD, the following must be excluded:

Calculate FIB-4 for all at-risk patients , including those with T2DM or obesity. If FIB-4 < 1.3, advanced fibrosis is ruled out with high negative predictive value; these patients should repeat non-invasive tests in 2 – 3 years and focus on cardiovascular disease (CVD) risk reduction. [⁴,³³,³].

For FIB-4 1.3 – 2.67, perform a secondary non-invasive test such as VCTE or the Enhanced Liver Fibrosis (ELF) test. If results remain indeterminate, patients should be reassessed annually or referred based on clinical suspicion [⁴,³].

Patients with FIB-4 > 2.67 or LSM \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\geq$\end{document}≥ 12 kPa are considered high-risk and require hepatology referral. Confirmed advanced fibrosis (F3/F4) necessitates the initiation of MASH management, biannual HCC screening, and formal variceal risk assessment [⁴,³³,³].

Mandatory biannual abdominal ultrasound (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\pm$\end{document}± alpha-fetoprotein) for all patients with cirrhosis (F4) and considered for those with F3 based on individual risk [³⁰,³⁵,³⁸].

According to the Baveno VII criteria, screening endoscopy for esophageal varices can be safely avoided in patients with a liver stiffness measurement < 20 kPa AND a platelet count > 150,000/μL. Conversely, those not meeting these criteria require endoscopic screening [⁴,⁴⁸,³].

Explicit referral for liver transplantation assessment is triggered by a MELD-Na score \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\geq$\end{document}≥ 15, the first occurrence of hepatic decompensation (ascites, encephalopathy, or jaundice), or HCC within Milan criteria [⁴,⁴⁸] Decompensation Monitoring: Regular clinical surveillance for complications such as ascites, hepatic encephalopathy, and variceal hemorrhage is essential for patients cACLD [⁴⁸,³].

Routine immunization against hepatitis A (HAV), hepatitis B (HBV), and pneumococcus, as well as annual influenza and COVID-19 boosters, is necessary to prevent acute-on-chronic liver failure [¹,⁴,⁴⁸].

Targeted intervention for sarcopenia involves a protein-rich diet (1.2 – 1.5 g/kg/day) and Vitamin D optimization to preserve bone mineral density [⁴⁸].

Regular screening for osteoporosis/osteopenia and Vitamin D deficiency [¹,⁴⁸].

Beyond general weight loss, the Mediterranean Diet is uniquely effective due to its high concentration of monounsaturated fatty acids and antioxidants. These components directly influence hepatic de novo lipogenesis and systemic inflammation, leading to superior metabolic outcomes compared to standard low-fat diets [⁴⁹,⁴,⁴⁸].

Guidelines recommend 150 minutes of moderate-intensity aerobic activity or 75 – 150 minutes of vigorous activity weekly. Exercise improves hepatic insulin sensitivity and reduces liver fat even in the absence of significant weight change [¹,⁴,⁴⁸].

A selective thyroid hormone receptor-\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\beta$\end{document}β (THR-\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\beta$\end{document}β) agonist approved for non-cirrhotic MASH. It achieved MASH resolution in ~30% and fibrosis improvement in 25% of trial participants. [⁹].

Semaglutide and Tirzepatide have demonstrated MASH resolution rates exceeding 60%. While primary indications are obesity and T2DM, they significantly improve the metabolic environment and reduce liver stiffness [⁴²,⁵⁰].

It is critical to distinguish between the evidence levels of current therapeutics [⁴]. Resmetirom and Tirzepatide have demonstrated efficacy based on histological endpoints (biopsy-proven MASH resolution and fibrosis reversal) [⁹,⁵⁰], which remain the gold standard for regulatory approval. Conversely, many early-stage incretin studies rely on surrogate outcomes, such as significant reductions in MRI-PDFF (Magnetic Resonance Imaging Proton Density Fat Fraction) or LSM, which correlate with clinical improvement but do not yet confirm tissue-level fibrosis regression [⁴²,³³].

At 5 years post-surgery, up to 84% of patients achieve MASH resolution and 70% show fibrosis improvement [⁴⁸].

Large observational studies confirm that bariatric surgery reduces 10-year major liver-related events (2.3% vs. 8.5%) and cardiovascular events (8.5% vs. 15.7%) compared to non-surgical care [⁴⁸,³²].

Utilize the FIB-4 Index as a primary case-finding tool for all diabetic patients, rather than relying on transaminases, which serve as poor rule-out tools [³,⁷]

Elevated or indeterminate FIB-4 scores must be followed by Liver Stiffness Measurement via VCTE (Vibration-Controlled Transient Elastography) to improve positive predictive value [⁴,³³,³].

Statins are first-line, safe in MASLD, and may reduce the risk of HCC.

In patients with T2DM and high cardiovascular risk, SGLT2 inhibitors or GLP-1 RAs are preferred for their dual hepatic and cardioprotective benefits [⁴²,⁴³]

Non-selective beta-blockers, particularly carvedilol, are the standard of care to reduce portal pressure and prevent the first episode of decompensation. Routine endoscopic screening for varices is not required if Liver stiffness measurement < 20 kPa and platelets > 150×10^9/L [⁴,⁴⁸,³].

While GLP-1 and GIP/GLP-1 receptor agonists (e.g., Tirzepatide) are highly effective for weight loss, up to 25 – 40% of weight lost can be lean muscle mass. To prevent a decline in metabolic rate, these therapies must be paired with mandatory resistance training and optimized protein intake [⁴²,⁵⁰,¹⁰].

Overcoming "anabolic resistance" in MASLD requires a high protein intake (1.2 – 1.5 g/kg/day), distributed boluses of protein throughout the day. Adherence to a Mediterranean dietary pattern is the gold standard, as its monounsaturated fats and antioxidants specifically reduce systemic inflammation and de novo lipogenesis [⁴⁹,¹⁶].

Resistance exercise remains a cornerstone non-pharmacological ’liver-sparing’ intervention. By improving the glucose-clearing capacity of the skeletal muscle – the body’s largest metabolic organ – resistance training reduces the metabolic load on the liver independently of total weight loss [¹⁹,¹²].